Single-inhaler triple therapy in patients with advanced COPD: Bayesian modeling of the healthcare resource utilization data and associated costs from the IMPACT trial
dc.contributor.author | Gabrio, A | |
dc.contributor.author | Gunsoy, NB | |
dc.contributor.author | Baio, G | |
dc.contributor.author | Martin, A | |
dc.contributor.author | Paly, VF | |
dc.contributor.author | Risebrough, N | |
dc.contributor.author | Halpin, DMG | |
dc.contributor.author | Singh, D | |
dc.contributor.author | Wise, RA | |
dc.contributor.author | Han, MK | |
dc.contributor.author | Martinez, FJ | |
dc.contributor.author | Criner, GJ | |
dc.contributor.author | Martin, N | |
dc.contributor.author | Lipson, DA | |
dc.contributor.author | Ismaila, AS | |
dc.date.accessioned | 2023-06-21T10:21:16Z | |
dc.date.issued | 2022-07-25 | |
dc.date.updated | 2023-06-20T09:00:17Z | |
dc.description.abstract | OBJECTIVES: In the IMPACT trial (NCT02164513), triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) showed clinical benefit compared with dual therapy with either FF/VI or UMEC/VI in the treatment of chronic obstructive pulmonary disease (COPD). We used data from IMPACT to determine whether this translated into differences in COPD-related healthcare resource utilization (HRU) costs in a United Kingdom (UK) setting. METHODS: In a within-trial analysis, individual patient data from the IMPACT intention-to-treat (ITT) population were analyzed to estimate rates of COPD-related HRU with FF/UMEC/VI, FF/VI, or UMEC/VI. A Bayesian approach was applied to address issues typically encountered with this kind of data, namely data missing due to early study withdrawal, subjects with zero reported HRU, and skewness. Rates of HRU were estimated under alternate assumptions of data being missing at random (MAR) or missing not at random (MNAR). UK-specific unit costs were then applied to estimated HRU rates to calculate treatment-specific costs. RESULTS: Under each MNAR scenario, per patient per year (PPPY) rates of COPD-related HRU were lowest amongst those patients who received treatment with FF/UMEC/VI compared with those receiving either FF/VI or UMEC/VI. Although absolute HRU rates and costs were typically higher for all treatment groups under MNAR scenarios versus MAR, final economic conclusions were robust to patient withdrawals. CONCLUSIONS: PPPY rates were typically lower with FF/UMEC/VI versus FF/VI or UMEC/VI. | en_GB |
dc.description.sponsorship | GlaxoSmithKline | en_GB |
dc.format.extent | 1633-1642 | |
dc.identifier.citation | Vol. 17, pp. 1633-1642 | en_GB |
dc.identifier.doi | https://doi.org/10.2147/COPD.S342244 | |
dc.identifier.uri | http://hdl.handle.net/10871/133451 | |
dc.identifier | ORCID: 0000-0003-2009-4406 (Halpin, David MG) | |
dc.identifier | ScopusID: 57419799500 | 7005149597 (Halpin, David MG) | |
dc.language.iso | en | en_GB |
dc.publisher | Dove Press | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/35915738 | en_GB |
dc.rights | © 2022 Gabrio et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). | en_GB |
dc.subject | COPD | en_GB |
dc.subject | cost | en_GB |
dc.subject | healthcare resource use | en_GB |
dc.subject | single-inhaler triple therapy | en_GB |
dc.title | Single-inhaler triple therapy in patients with advanced COPD: Bayesian modeling of the healthcare resource utilization data and associated costs from the IMPACT trial | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-06-21T10:21:16Z | |
dc.identifier.issn | 1176-9106 | |
exeter.place-of-publication | New Zealand | |
dc.description | This is the final version. Available on open access from Dove Press via the DOI in this record. | en_GB |
dc.description | Data Availability: The datasets supporting the results reported in this manuscript are not publicly available. Access to the raw data may be granted on reasonable request to the corresponding author dependent on the intended use and subject to third-party agreements. | en_GB |
dc.identifier.eissn | 1178-2005 | |
dc.identifier.journal | International Journal of Chronic Obstructive Pulmonary Disease | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/3.0/ | en_GB |
dcterms.dateAccepted | 2022-06-25 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2022-07-25 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-06-21T10:18:52Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2023-06-21T10:21:21Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2022-07 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2022 Gabrio et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).